
























![]()
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call April 28, 2026 6:30 AM EDT
Company Participants
Guido Oelkers - CEO & President
Lydia Abad-Franch - Senior VP, Head of R&D & Medical Affairs and Chief Medical Officer
Henrik Stenqvist - Chief Financial Officer
Conference Call Participants
Xue Chen - Barclays Bank PLC, Research Division
Christopher Uhde - SEB, Research Division
Kirsty Ross-Stewart - BNP Paribas, Research Division
Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division
Harry Gillis - Joh. Berenberg, Gossler & Co. KG, Research Division
Georg Tigalonov-Bjerke - ABG Sundal Collier Holding ASA, Research Division
Presentation
Operator
Ladies and gentlemen, welcome to the Sobi Q1 2026 Report Conference Call and Live Webcast. I am Valentina, the Chorus Call operator. [Operator Instructions] The conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Guido Oelkers, CEO. Please go ahead.
Guido Oelkers
CEO & President
Thank you. Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the first quarter 2026 conference call for investors and analysts. Our presentation was posted on sobi.com earlier today. Please turn to the next slide. We would like to remind you of the usual provisions on statements about expectations and projections of future events. Unless stated otherwise, we are making comments that mostly relate to the first quarter at constant exchange rates in million Swedish krona.
Please turn to the next slide. Today, we plan to cover the key aspects of our Q1 report. I'm joined by Henrik Stenqvist, our CFO; and Lydia Abad-Franch, Head of R&D and Chief Medical Officer. We plan to review the presentation first and then have a Q&A until around 1:30 p.m. Central Eastern European Time. [Operator Instructions] Please turn to the next slide.
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。